Grant received in 2024

DCCC has funded 200,000 DKK to the project.

In Denmark, the implementation of home-based treatment for patients with haematological malignancies are well under way. However, we do not know the actual costs and we lack knowledge on the advantages and disadvantages for patients, relatives, and health professionals.

This initiative will investigate the most effective organization of home treatment for haematological cancer patients. A study will be conducted to gain a deeper understanding of the benefits and drawbacks of different home treatment models across the country. The research will focus on identifying organisational structures that offer the greatest economic and resource-related benefits, while also ensuring high quality of life and satisfaction for patients and their families.

The aim is to establish an evidence-based foundation for concrete recommendations on how to optimise and implement home treatment organisation and expansion at a national level. The findings are expected to inspire other similar home treatment programs in haematology, and the methodology may also be applied to assess other existing home care options.

The funding will be used for protocol development, establishing collaboration agreements, and coordinating data management. Additionally, the funds will facilitate cross-regional cooperation, essential for the study’s success. Some of the funding will be allocated to organising national, interdisciplinary project meetings, which will include patient representatives to ensure a comprehensive perspective.

Multidisciplinary organisation
The study is rooted in the National Interdisciplinary Hematological Research Network in Denmark, with links to the DMCG groups established through the participating physicians in the project team.

Project stakeholder

Region Zealand

• Kristina Nørskov, Nurse, Postdoc, PhD, Department of Hematology, Zealand University Hospital. Primary contact, mail: knors@regionsjaelland.dk
• Nicolai Grønne, Registrar, PhD, Department of Hematology, Zealand University Hospital, Roskilde

Capital Region of Denmark

• Iben Husted Nielsen, Clinical Nurse Specialist, Postdoc, PhD, Department of Hematology, Rigshospitalet
• Lars Kjeldsen, Consultant, DMSc, Department of Hematology, Rigshospitalet
• Mary Jarden, Professor, Head of Research Nursing, PhD, Department of Hematology, Rigshospitalet
• Tine Johannesen, Clinical Nurse Specialist, Department of Hematology, Rigshospitalet

Region of Southern Denmark

• Tine Rosenberg, Research Coordinator, MSc, Haematology Research Unit and Quality of Life Research Center, Odense University Hospital
• Jannie Kirkegaard, Project Coordinator, Haematology Research Unit, Odense University Hospital
• Thomas Lund, Consultant, PhD, Department of Hematology, Odense University Hospital
• Maja Kjær Rasmussen, Health Economist, Centre for Innovative Medical Technology, Odense University Hospital

Central Denmark Region

• Camilla Thim Damgård, Clinical Nurse Specialist, Department of Hematology, Aarhus University Hospital
• Trine Silkjær, Head Consultant, PhD, Department of Hematology, Aarhus University Hospital
• Maja Ølholm Vase, Specialty Registrar, PhD, Department of Hematology, Aarhus University Hospital

North Denmark Region

• Helle Enggaard, Nurse, Postdoc, PhD, Clinical Nursing Research Unit & Clinical Cancer Research Center, Aalborg University Hospital
• Ann Ozimek Rittig, Nurse, Department of Hematology, Aalborg University Hospital
• Marianne Tang Severinsen, Consultant, Professor, Department of Hematology, Aalborg University Hospital

Patient representatives

• Rita O. Christensen, Chair, Patient organisation for Lymphoma, Leukemia and MDS

Carsten Levin, Chair, Danish Myeloma Association